Pure Bioscience, Inc. financial data

Symbol
PURE on OTC
Industry
Miscellaneous Chemical Products
Location
771 Jamacha Road #512, El Cajon, CA
State of incorporation
Delaware
Fiscal year end
July 31
Former names
PURE BIOSCIENCE (to 3/17/2011), INNOVATIVE MEDICAL SERVICES (to 9/2/2003)
Latest financial report
10-Q - Q1 2024 - Jun 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 215 % -51%
Quick Ratio 13.3 % -59.9%
Debt-to-equity -270 %
Return On Equity 405 %
Return On Assets -239 % -79.6%
Operating Margin -169 % +32%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares +0.45%
Common Stock, Shares, Outstanding 112M shares +0.45%
Entity Public Float 4.91M USD -65.9%
Common Stock, Value, Issued 1.12M USD +0.45%
Weighted Average Number of Shares Outstanding, Basic 112M shares +0.45%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +0.45%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.09M USD +24.6%
Revenue from Contract with Customer, Excluding Assessed Tax 2.09M USD +23.9%
Research and Development Expense 303K USD +4.12%
Operating Income (Loss) -3.52M USD +15.3%
Nonoperating Income (Expense) -110K USD -746%
Net Income (Loss) Attributable to Parent -3.63M USD +12.9%
Earnings Per Share, Basic -0.04 USD/shares +20%
Earnings Per Share, Diluted -0.04 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 442K USD -43.4%
Accounts Receivable, after Allowance for Credit Loss, Current 234K USD +24.5%
Inventory, Net 74K USD -50.3%
Assets, Current 869K USD -29.4%
Property, Plant and Equipment, Net 51K USD -91.4%
Assets 920K USD -49.6%
Accounts Payable, Current 506K USD +17.1%
Accrued Liabilities, Current 160K USD +16.8%
Liabilities, Current 666K USD +17%
Liabilities 3.07M USD
Retained Earnings (Accumulated Deficit) -136M USD -2.74%
Stockholders' Equity Attributable to Parent -2.15M USD -271%
Liabilities and Equity 920K USD -49.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -440K USD +51.2%
Net Cash Provided by (Used in) Financing Activities 785K USD
Net Cash Provided by (Used in) Investing Activities -37K USD +31.5%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 112M shares +0.45%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 345K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 517K USD -39.6%
Deferred Tax Assets, Valuation Allowance 30.3M USD +2.78%
Deferred Tax Assets, Gross 30.3M USD +2.78%
Payments to Acquire Property, Plant, and Equipment 37K USD -31.5%
Property, Plant and Equipment, Gross 1.62M USD -2.71%
Deferred Tax Assets, Operating Loss Carryforwards 28.2M USD +3.07%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 133M USD +0.17%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 80K USD +27%
Interest Expense 111K USD +1133%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%